Mesoblast Webcast – Update on COVID-19 ARDS Trial
December 17 2020 - 10:06PM
Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in
allogeneic cellular medicines for inflammatory diseases, will host
a webcast today to provide an update on the randomized controlled
trial of remestemcel-L in ventilator-dependent patients with
moderate to severe acute respiratory distress syndrome (ARDS) due
to COVID-19 infection.
The webcast will begin at 2.00pm AEDT, Friday, December 18;
10.00pm EST, Thursday, December 17, 2020. It can be accessed via
https://webcast.boardroom.media/mesoblast-limited/20201218/NaN5fdc08a4367467001988bc8f
The archived webcast will be available on the Investor page of
the Company’s website: www.mesoblast.com
About Mesoblast Mesoblast Limited (ASX:MSB;
Nasdaq:MESO) is a world leader in developing allogeneic
(off-the-shelf) cellular medicines. The Company has leveraged its
proprietary mesenchymal lineage cell therapy technology platform to
establish a broad portfolio of late-stage product candidates.
Mesoblast has a strong and extensive global intellectual property
portfolio with protection extending through to at least 2040 in all
major markets. The Company’s proprietary manufacturing processes
yield industrial-scale, cryopreserved, off-the-shelf, cellular
medicines. These cell therapies, with defined pharmaceutical
release criteria, are planned to be readily available to patients
worldwide.
Remestemcel-L is being developed for inflammatory diseases in
children and adults including steroid refractory acute graft versus
host disease and moderate to severe acute respiratory distress
syndrome. Mesoblast has completed Phase 3 trials of
rexelemestrocel-L for advanced heart failure and chronic low back
pain. Two products have been commercialized in Japan and Europe by
Mesoblast’s licensees, and the Company has established commercial
partnerships in Europe and China for certain Phase 3 assets.
Mesoblast has locations in Australia, the United States and
Singapore and is listed on the Australian Securities Exchange (MSB)
and on the Nasdaq (MESO). For more information, please see
www.mesoblast.com, LinkedIn: Mesoblast Limited and Twitter:
@Mesoblast
Forward-Looking StatementsThis announcement
includes forward-looking statements that relate to future events or
our future financial performance and involve known and unknown
risks, uncertainties and other factors that may cause our actual
results, levels of activity, performance or achievements to differ
materially from any future results, levels of activity, performance
or achievements expressed or implied by these forward-looking
statements. All statements other than statements of historical fact
are forward-looking statements, which are often indicated by terms
such as “anticipate,” “believe,” “could,” “estimate,” “expect,”
“goal,” “intend,” “likely,” “look forward to,” “may,” “plan,”
“potential,” “predict,” “project,” “should,” “will,” “would” and
similar expressions and variations thereof. We make such
forward-looking statements pursuant to the safe harbor provisions
of the Private Securities Litigation Reform Act of 1995 and other
federal securities laws. Forward-looking statements should not be
read as a guarantee of future performance or results, and actual
results may differ from the results anticipated in these
forward-looking statements, and the differences may be material and
adverse. The risks, uncertainties and other factors that may impact
our forward-looking statements include, but are not limited to: the
timing, progress and results of Mesoblast’s preclinical and
clinical studies; Mesoblast’s ability to advance product candidates
into, enroll and successfully complete, clinical studies; the
timing or likelihood of regulatory filings and approvals; and the
pricing and reimbursement of Mesoblast’s product candidates, if
approved; Mesoblast’s ability to establish and maintain
intellectual property on its product candidates and Mesoblast’s
ability to successfully defend these in cases of alleged
infringement. You should read this press release together with our
risk factors, in our most recently filed reports with the SEC or on
our website. Uncertainties and risks that may cause Mesoblast’s
actual results, performance or achievements to be materially
different from those which may be expressed or implied by such
statements, and accordingly, you should not place undue reliance on
these forward-looking statements. Unless required by law, we do not
undertake any obligations to publicly update or revise any
forward-looking statements, whether as a result of new information,
future developments or otherwise.
Release authorized by the Chief Executive
For more information, please contact:Corporate
Communications / InvestorsSchond Greenway T: +1 212 880
2060E: schond.greenway@mesoblast.com |
Paul Hughes T: +61 3 9639 6036 E: paul.hughes@mesoblast.com |
|
|
Media Kristen
Bothwell T: +1 917 613 5434E: kbothwell@rubenstein.com |
|
Mesoblast (NASDAQ:MESO)
Historical Stock Chart
From Jun 2024 to Jul 2024
Mesoblast (NASDAQ:MESO)
Historical Stock Chart
From Jul 2023 to Jul 2024